Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q3 FY25 results · Oct–Dec 2024
Supriya Lifescience reported revenue from operations of ₹185.65 crore (up 32.5% from Q3 FY24) and net profit of ₹46.78 crore (up 57.1% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 185.65 | 140.07 | +32.5% | 166.10 | +11.8% |
| Other income | 2.10 | 3.06 | −31.5% | 2.52 | −16.7% |
| Total income | 187.75 | 143.14 | +31.2% | 168.62 | +11.3% |
| Profit before tax | 62.58 | 40.10 | +56.1% | 62.06 | +0.8% |
| Net profit for the period | 46.78 | 29.79 | +57.1% | 46.15 | +1.4% |
| EPS, basic (₹) | 5.82 | 3.70 | +57.3% | 5.71 | +1.9% |
| Net margin (%) | 25.2 | 21.3 | 27.8 |
Standalone
- Filed with BSE
- 24 Jan 2025, 17:39 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE